Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from GlucoTrack ( (GCTK) ).
Glucotrack, Inc. has begun enrolling patients for its short-term clinical study of a novel continuous blood glucose monitor designed for real-time, accurate blood readings without external components. This implantable device promises a less intrusive solution for diabetes management, with study results anticipated within 6-8 weeks. The study is led by renowned cardiologist Dr. Alexandre Abizaid and conducted at Brazil’s top cardiology hospital.
Find detailed analytics on GCTK stock on TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Hans Mosesmann About Intel Stock
- Canaccord Pounds the Table on Archer Aviation Stock
- ‘Don’t Let the Law of Large Numbers Scare You,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
